Updating Registration Information Within 30 Days of Change

1. Key takeaways

Under 21 CFR 807.22(b)(2), when registration information, as described in 807.25(b), changes, the update must be completed within 30 days of the change. The consequence of failing to update on time is that the establishment enters the failed to register status: it is no longer considered an active establishment, its registration information may not be displayed on the FDA website, and as a downstream effect the lapse may interfere with customs clearance of its products. For foreign manufacturers, this single rule connects a routine administrative detail, keeping registration data current, directly to the free flow of goods into the United States.

• Changes to registration information: update within 30 days of the change, under 21 CFR 807.22(b)(2).
• Registration information means the content described in 21 CFR 807.25(b), which was amended effective 2020-04-02 (85 FR 18442).
• A missed update places the establishment in the failed to register status under 21 CFR 807.22(c), with visible consequences on the FDA website.
• Import Alert 99-34 allows detention without physical examination of products from firms without valid registration and/or listing (current edition amended 2023-10-18).

2. Legal basis

The 30-day update rule draws its force from several interlocking provisions: the rule itself, the definition of what counts as registration information, the status consequence, the exemption procedure, and the import enforcement mechanism that punishes a lapsed registration at the border.

3. Expert insights

Insight 1: The 30-day rule applies to registration information; listing information follows a different rule.

Under 21 CFR 807.22(b)(2), the 30-day update obligation targets the registration information described in 807.25(b). That content includes the establishment name and mailing address, the website address, the name, address, telephone number, fax number and email address of the owner or operator, the establishment types of activity, and the official correspondent information, among other items. Listing information is governed by the different timing rule in (b)(4), which addresses updates at other times. Treating the two as one blended obligation is a common source of confusion; a company should maintain two distinct processes, one for registration data changes and one for listing data changes, each with its own timing rule.

Insight 2: The official correspondent is the critical role for receiving FDA communications.

Under 21 CFR 807.35(a), after FDA completes its verification of the initial registration information, it assigns a registration number to the establishment and an owner or operator identification number to the establishment’s owner or operator, and both numbers are sent to the official correspondent. The transmission is by electronic mail; establishments that have obtained an exemption from electronic submission receive the numbers by mail. If the official correspondent’s mailbox becomes inactive, the company effectively stops receiving key FDA communications, including the very numbers that anchor its registration. Monitoring that mailbox is therefore not an administrative nicety but a control point on which the entire registration chain depends.

Insight 3: The transmission path of a status lapse runs from registration to website to customs.

The failed to register status means the establishment is not considered active. That in turn means the registration information may not appear on the FDA website. At clearance, the importer or broker cannot demonstrate that the establishment’s registration is valid. The result is detention without physical examination under Import Alert 99-34, which applies to firms without valid registration and/or listing. The chain is administrative at the start but commercial at the end: what it produces in practice is detained cargo, not a fine notice. This is why the 30-day update rule deserves the same operational discipline as any shipping deadline.

Insight 4: Recovery requires submission plus FDA processing, not automatic restoration.

Under 21 CFR 807.22(c), the status is restored when the owner or operator submits the required information to FDA and FDA has completed processing of it. Submission alone does not flip the status. Companies that submit overdue information should therefore reserve processing time before scheduling shipments, and should not assume that a filed update will be reflected on the FDA website immediately. The gap between submission and restored status is precisely when detention risk is highest, and it should be managed as an explicit waiting period in the shipping plan.

4. Practical recommendations

The measures below operationalize the 30-day rule so that changes are caught and updated inside the regulatory window.

• Maintain a registration information change list covering the establishment name, address, website, owner or operator contact details, establishment types of activity, and the official correspondent, six categories in total, where any single change triggers the 30-day update.
• Assign the official correspondent role to a person expected to remain in post long term, with a stable mailbox, and establish monitoring of that mailbox.
• Treat change updates and the annual update as two independent actions; one cannot be offset against the other.
• When submitting overdue information to restore a lapsed status, reserve FDA processing time before arranging shipments.
• Build a cross-department change notification mechanism so that events such as a company renaming or relocation reach the registration information within 30 days.

5. Verification checklist

Confirm each item below before relying on the establishment’s registration status for a shipment or a submission.

• □ The six categories of registration information under 21 CFR 807.25(b) have been listed and a monitoring owner assigned.
• □ The official correspondent’s mailbox is functional and monitored by a designated person.
• □ The 30-day change update process has been established and leaves an audit trail.
• □ It has been confirmed that change updates and the annual update belong to two separate processes.
• □ After a status lapse, FDA processing time has been reserved before shipping resumed.
• □ Submission evidence has been retained for every change update.

Regulatory information verified as of October 28, 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, US Agent and local testing support for the United States market. Our team manages FDA establishment registration and listing, 510(k)/De Novo/PMA submissions, and supports post-market reporting obligations. Business enquiries: info@grzanglobal.com